BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 20530286)

  • 1. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
    Klechevsky E; Flamar AL; Cao Y; Blanck JP; Liu M; O'Bar A; Agouna-Deciat O; Klucar P; Thompson-Snipes L; Zurawski S; Reiter Y; Palucka AK; Zurawski G; Banchereau J
    Blood; 2010 Sep; 116(10):1685-97. PubMed ID: 20530286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
    von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
    J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production.
    Meyer-Wentrup F; Benitez-Ribas D; Tacken PJ; Punt CJ; Figdor CG; de Vries IJ; Adema GJ
    Blood; 2008 Apr; 111(8):4245-53. PubMed ID: 18258799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.
    Idoyaga J; Lubkin A; Fiorese C; Lahoud MH; Caminschi I; Huang Y; Rodriguez A; Clausen BE; Park CG; Trumpfheller C; Steinman RM
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2384-9. PubMed ID: 21262813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient generation of a monoclonal antibody against the human C-type lectin receptor DCIR by targeting murine dendritic cells.
    Heidkamp GF; Neubert K; Haertel E; Nimmerjahn F; Nussenzweig MC; Dudziak D
    Immunol Lett; 2010 Aug; 132(1-2):69-78. PubMed ID: 20566350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
    Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
    J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DCIR interacts with ligands from both endogenous and pathogenic origin.
    Bloem K; Vuist IM; van den Berk M; Klaver EJ; van Die I; Knippels LM; Garssen J; García-Vallejo JJ; van Vliet SJ; van Kooyk Y
    Immunol Lett; 2014; 158(1-2):33-41. PubMed ID: 24239607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets.
    Kastenmüller K; Wille-Reece U; Lindsay RW; Trager LR; Darrah PA; Flynn BJ; Becker MR; Udey MC; Clausen BE; Igyarto BZ; Kaplan DH; Kastenmüller W; Germain RN; Seder RA
    J Clin Invest; 2011 May; 121(5):1782-96. PubMed ID: 21540549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production.
    Meyer-Wentrup F; Cambi A; Joosten B; Looman MW; de Vries IJ; Figdor CG; Adema GJ
    J Leukoc Biol; 2009 Mar; 85(3):518-25. PubMed ID: 19028959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
    Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
    J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes.
    Graham JP; Authie P; Yu CI; Zurawski SM; Li XH; Marches F; Flamar AL; Acharya A; Banchereau J; Palucka AK
    Vaccine; 2016 Sep; 34(41):4857-4865. PubMed ID: 27595442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
    Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
    BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.
    Schreibelt G; Klinkenberg LJ; Cruz LJ; Tacken PJ; Tel J; Kreutz M; Adema GJ; Brown GD; Figdor CG; de Vries IJ
    Blood; 2012 Mar; 119(10):2284-92. PubMed ID: 22234694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
    Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif.
    Bates EE; Fournier N; Garcia E; Valladeau J; Durand I; Pin JJ; Zurawski SM; Patel S; Abrams JS; Lebecque S; Garrone P; Saeland S
    J Immunol; 1999 Aug; 163(4):1973-83. PubMed ID: 10438934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
    Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
    EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross-tolerance.
    Flacher V; Tripp CH; Mairhofer DG; Steinman RM; Stoitzner P; Idoyaga J; Romani N
    EMBO Mol Med; 2014 Sep; 6(9):1191-204. PubMed ID: 25085878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced dendritic cell-induced immune responses mediated by the novel C-type lectin receptor mDCAR1.
    Kaden SA; Kurig S; Vasters K; Hofmann K; Zaenker KS; Schmitz J; Winkels G
    J Immunol; 2009 Oct; 183(8):5069-78. PubMed ID: 19786536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.
    Hutten TJ; Thordardottir S; Fredrix H; Janssen L; Woestenenk R; Tel J; Joosten B; Cambi A; Heemskerk MH; Franssen GM; Boerman OC; Bakker LB; Jansen JH; Schaap N; Dolstra H; Hobo W
    J Immunol; 2016 Oct; 197(7):2715-25. PubMed ID: 27566820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28.
    Pufnock JS; Cigal M; Rolczynski LS; Andersen-Nissen E; Wolfl M; McElrath MJ; Greenberg PD
    Blood; 2011 Jun; 117(24):6542-51. PubMed ID: 21493800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.